These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 32662299

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
    Reinke Y, Gross S, Eckerle LG, Hertrich I, Busch M, Busch R, Riad A, Rauch BH, Stasch JP, Dörr M, Felix SB.
    Eur J Pharmacol; 2015 Nov 15; 767():1-9. PubMed ID: 26407652
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
    Chester M, Seedorf G, Tourneux P, Gien J, Tseng N, Grover T, Wright J, Stasch JP, Abman SH.
    Am J Physiol Lung Cell Mol Physiol; 2011 Nov 15; 301(5):L755-64. PubMed ID: 21856817
    [Abstract] [Full Text] [Related]

  • 7. Responsiveness of rat aorta and pulmonary artery to cGMP generators in the presence of thiol or heme oxidant.
    Tawa M, Yamashita Y, Masuoka T, Nakano K, Yoshida J, Nishio M, Ishibashi T.
    J Pharmacol Sci; 2019 May 15; 140(1):43-47. PubMed ID: 31036520
    [Abstract] [Full Text] [Related]

  • 8. Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by the Protoporphyrin IX Mimetic Cinaciguat.
    Kollau A, Opelt M, Wölkart G, Gorren ACF, Russwurm M, Koesling D, Mayer B, Schrammel A.
    Mol Pharmacol; 2018 Feb 15; 93(2):73-78. PubMed ID: 29138269
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K, Sydykov A, Tian X, Mamazhakypov A, Neupane B, Luitel H, Weissmann N, Seeger W, Grimminger F, Kretschmer A, Stasch JP, Ghofrani HA, Schermuly RT.
    Int J Cardiol; 2016 Aug 01; 216():85-91. PubMed ID: 27140341
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.
    Chamorro V, Morales-Cano D, Milara J, Barreira B, Moreno L, Callejo M, Mondejar-Parreño G, Esquivel-Ruiz S, Cortijo J, Cogolludo Á, Barberá JA, Perez-Vizcaino F.
    PLoS One; 2018 Aug 01; 13(1):e0191239. PubMed ID: 29364918
    [Abstract] [Full Text] [Related]

  • 14. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.
    Badejo AM, Nossaman VE, Pankey EA, Bhartiya M, Kannadka CB, Murthy SN, Nossaman BD, Kadowitz PJ.
    Am J Physiol Heart Circ Physiol; 2010 Oct 01; 299(4):H1153-9. PubMed ID: 20639220
    [Abstract] [Full Text] [Related]

  • 15. A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation.
    Sawabe T, Chiba T, Kobayashi A, Nagasaka K, Aihara K, Takaya A.
    Pharmacol Res Perspect; 2019 Apr 01; 7(2):e00463. PubMed ID: 30873284
    [Abstract] [Full Text] [Related]

  • 16. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
    Follmann M, Griebenow N, Hahn MG, Hartung I, Mais FJ, Mittendorf J, Schäfer M, Schirok H, Stasch JP, Stoll F, Straub A.
    Angew Chem Int Ed Engl; 2013 Sep 02; 52(36):9442-62. PubMed ID: 23963798
    [Abstract] [Full Text] [Related]

  • 17. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A, Bowman L, D'Arsigny CL, Archer SL.
    Clin Pharmacol Ther; 2015 Jan 02; 97(1):88-102. PubMed ID: 25670386
    [Abstract] [Full Text] [Related]

  • 18. Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism.
    Kline JA, Puskarich MA, Pike JW, Zagorski J, Alves NJ.
    Nitric Oxide; 2020 Mar 01; 96():20-28. PubMed ID: 31940502
    [Abstract] [Full Text] [Related]

  • 19. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
    Sandner P, Becker-Pelster EM, Stasch JP.
    Nitric Oxide; 2018 Jul 01; 77():88-95. PubMed ID: 29738821
    [Abstract] [Full Text] [Related]

  • 20. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
    Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, Kretschmer A, Stasch JP, Seeger W, Ghofrani HA, Schermuly RT.
    PLoS One; 2012 Jul 01; 7(8):e43433. PubMed ID: 22912874
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.